Neuropace, Inc. ( (NPCE) ) has released its Q1 earnings. Here is a breakdown of the information Neuropace, Inc. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NeuroPace, Inc., based in Mountain View, California, is a medical device company specializing in innovative treatments for epilepsy, notably through its RNS System, a brain-responsive platform designed to reduce seizures in patients with drug-resistant epilepsy.
In its first quarter of 2025, NeuroPace reported a record revenue of $22.5 million, marking a 24% increase from the previous year, driven by growing demand for its RNS System. The company also raised its full-year revenue guidance to between $93 million and $97 million.
Key financial highlights include a 26% year-over-year growth in RNS System revenue, a strong gross margin of 77%, and a reduction in net loss to $6.6 million from $8.9 million in the prior year. NeuroPace also announced a strategic shift to focus on its core RNS System product line, ceasing its distribution of SEEG products by early 2026.
Looking ahead, NeuroPace aims to expand its market reach by targeting new patient populations and advancing its product development, including AI-powered software. The management remains optimistic about sustaining revenue growth and enhancing long-term value creation.